Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iridex (IRIX) Cash & Equivalents (2016 - 2025)

Iridex (IRIX) has 16 years of Cash & Equivalents data on record, last reported at $5.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 44.38% year-over-year to $5.6 million; the TTM value through Sep 2025 reached $5.6 million, up 44.38%, while the annual FY2024 figure was $2.4 million, 66.06% down from the prior year.
  • Cash & Equivalents reached $5.6 million in Q3 2025 per IRIX's latest filing, down from $6.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $28.0 million in Q2 2021 and bottomed at $2.4 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $12.7 million, with a median of $10.4 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 151.31% in 2021, then crashed 66.06% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $25.6 million in 2021, then tumbled by 45.55% to $13.9 million in 2022, then crashed by 49.48% to $7.0 million in 2023, then plummeted by 66.06% to $2.4 million in 2024, then surged by 133.47% to $5.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $5.6 million in Q3 2025, $6.8 million in Q2 2025, and $7.2 million in Q1 2025.